NasdaqGS:RXRXBiotechs
Is The Exit Of Nvidia And Novo Holdings Altering The Investment Case For Recursion Pharmaceuticals (RXRX)?
In recent months, Recursion Pharmaceuticals has seen major shareholders Nvidia and Novo Holdings fully exit their positions, ahead of its upcoming fourth-quarter 2025 earnings release and planned FDA discussions on lead candidate REC-4881.
These high-profile departures come as Recursion advances its AI-enabled drug discovery platform and clinical pipeline, testing investor conviction in its partnership-driven business model and capital needs.
Next, we’ll examine how the exit of high-profile...